<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20231107031103
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2&amp;v=2.17.9.post6+86293ac&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20231107031103" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Tue, 07 Nov 2023 08:11:06 +0000</lastbuilddate>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Patisiran is beneficial for the treatment of TTR cardiac amyloidosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37932423/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 6. doi: 10.1038/s41569-023-00955-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37932423/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37932423</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00955-2>10.1038/s41569-023-00955-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37932423</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Irene Fernández-Ruiz</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Patisiran is beneficial for the treatment of TTR cardiac amyloidosis</dc:title>
<dc:identifier>pmid:37932423</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00955-2</dc:identifier>
</item>
<item>
<title>Drug-eluting resorbable scaffolds are superior to angioplasty for infrapopliteal artery disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37932422/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 6. doi: 10.1038/s41569-023-00956-1. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37932422/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37932422</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00956-1>10.1038/s41569-023-00956-1</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37932422</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Karina Huynh</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Drug-eluting resorbable scaffolds are superior to angioplasty for infrapopliteal artery disease</dc:title>
<dc:identifier>pmid:37932422</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00956-1</dc:identifier>
</item>
<item>
<title>The Need for Randomized Trials to Define the Optimal Dose of Anticoagulants for Atrial Fibrillation in Chronic Kidney Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37931022/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 7;148(19):1455-1458. doi: 10.1161/CIRCULATIONAHA.123.066600. Epub 2023 Nov 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37931022/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37931022</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066600>10.1161/CIRCULATIONAHA.123.066600</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37931022</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Sean D Pokorney</dc:creator>
<dc:creator>Christopher B Granger</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>The Need for Randomized Trials to Define the Optimal Dose of Anticoagulants for Atrial Fibrillation in Chronic Kidney Disease</dc:title>
<dc:identifier>pmid:37931022</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066600</dc:identifier>
</item>
<item>
<title>Letter by Li et al Regarding Article, "Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study"</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37931021/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 7;148(19):1507-1508. doi: 10.1161/CIRCULATIONAHA.123.065349. Epub 2023 Nov 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37931021/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37931021</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065349>10.1161/CIRCULATIONAHA.123.065349</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37931021</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Sha Li</dc:creator>
<dc:creator>Jie Qian</dc:creator>
<dc:creator>Jian-Jun Li</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Letter by Li et al Regarding Article, "Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study"</dc:title>
<dc:identifier>pmid:37931021</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065349</dc:identifier>
</item>
<item>
<title>Cardiovascular Diseases in Nigeria: Current Status, Threats, and Opportunities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37931020/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 7;148(19):1441-1444. doi: 10.1161/CIRCULATIONAHA.123.063671. Epub 2023 Nov 6.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37931020/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37931020</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.063671>10.1161/CIRCULATIONAHA.123.063671</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37931020</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Okechukwu Samuel Ogah</dc:creator>
<dc:creator>Olanike Allison Orimolade</dc:creator>
<dc:creator>Tomilola Olamide Jinadu</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Cardiovascular Diseases in Nigeria: Current Status, Threats, and Opportunities</dc:title>
<dc:identifier>pmid:37931020</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.063671</dc:identifier>
</item>
<item>
<title>Religiosity/spirituality as a medical prescription</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930863/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 1:ehad725. doi: 10.1093/eurheartj/ehad725. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930863/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37930863</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad725>10.1093/eurheartj/ehad725</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930863</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nandan S Anavekar</dc:creator>
<dc:creator>Ankur Kalra</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Religiosity/spirituality as a medical prescription</dc:title>
<dc:identifier>pmid:37930863</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad725</dc:identifier>
</item>
<item>
<title>Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930776/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In an elderly, highly comorbid population with ≥moderate TR, patients receiving transfemoral EVOQUE transcatheter TV replacement had sustained TR reduction, significant increases in stroke volume and cardiac output, and high survival and low hospitalization rates with improved clinical, functional, and quality-of-life outcomes to one year. Funded by Edwards Lifesciences, TRISCEND ClinicalTrials.gov number, NCT04221490.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 1:ehad667. doi: 10.1093/eurheartj/ehad667. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: For patients with symptomatic, severe tricuspid regurgitation (TR), early results of transcatheter tricuspid valve (TV) intervention studies have shown significant improvements in functional status and quality of life associated with right-heart reverse remodelling. Longer-term follow-up is needed to confirm sustained improvements in these outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The prospective, single-arm, multicentre TRISCEND study enrolled 176 patients to evaluate the safety and performance of transcatheter TV replacement in patients with ≥moderate, symptomatic TR despite medical therapy. Major adverse events, reduction in TR grade and haemodynamic outcomes by echocardiography, and clinical, functional, and quality-of-life parameters are reported to one year.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Enrolled patients were 71.0% female, mean age 78.7 years, 88.0% ≥ severe TR, and 75.4% New York Heart Association classes III-IV. Tricuspid regurgitation was reduced to ≤mild in 97.6% (P &lt; .001), with increases in stroke volume (10.5 ± 16.8 mL, P &lt; .001) and cardiac output (0.6 ± 1.2 L/min, P &lt; .001). New York Heart Association class I or II was achieved in 93.3% (P &lt; .001), Kansas City Cardiomyopathy Questionnaire score increased by 25.7 points (P &lt; .001), and six-minute walk distance increased by 56.2 m (P &lt; .001). All-cause mortality was 9.1%, and 10.2% of patients were hospitalized for heart failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In an elderly, highly comorbid population with ≥moderate TR, patients receiving transfemoral EVOQUE transcatheter TV replacement had sustained TR reduction, significant increases in stroke volume and cardiac output, and high survival and low hospitalization rates with improved clinical, functional, and quality-of-life outcomes to one year. Funded by Edwards Lifesciences, TRISCEND ClinicalTrials.gov number, NCT04221490.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930776/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37930776</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad667>10.1093/eurheartj/ehad667</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930776</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Susheel Kodali</dc:creator>
<dc:creator>Rebecca T Hahn</dc:creator>
<dc:creator>Raj Makkar</dc:creator>
<dc:creator>Moody Makar</dc:creator>
<dc:creator>Charles J Davidson</dc:creator>
<dc:creator>Jyothy J Puthumana</dc:creator>
<dc:creator>Firas Zahr</dc:creator>
<dc:creator>Scott Chadderdon</dc:creator>
<dc:creator>Neil Fam</dc:creator>
<dc:creator>Geraldine Ong</dc:creator>
<dc:creator>Pradeep Yadav</dc:creator>
<dc:creator>Vinod Thourani</dc:creator>
<dc:creator>Mani A Vannan</dc:creator>
<dc:creator>William W O'Neill</dc:creator>
<dc:creator>Dee Dee Wang</dc:creator>
<dc:creator>Didier Tchétché</dc:creator>
<dc:creator>Nicolas Dumonteil</dc:creator>
<dc:creator>Laurent Bonfils</dc:creator>
<dc:creator>Laurent Lepage</dc:creator>
<dc:creator>Robert Smith</dc:creator>
<dc:creator>Paul A Grayburn</dc:creator>
<dc:creator>Rahul P Sharma</dc:creator>
<dc:creator>Christiane Haeffele</dc:creator>
<dc:creator>Vasilis Babaliaros</dc:creator>
<dc:creator>Patrick T Gleason</dc:creator>
<dc:creator>Sammy Elmariah</dc:creator>
<dc:creator>Ignacio Inglessis-Azuaje</dc:creator>
<dc:creator>Jonathan Passeri</dc:creator>
<dc:creator>Howard C Herrmann</dc:creator>
<dc:creator>Frank E Silvestry</dc:creator>
<dc:creator>Scott Lim</dc:creator>
<dc:creator>Dale Fowler</dc:creator>
<dc:creator>John G Webb</dc:creator>
<dc:creator>Robert Moss</dc:creator>
<dc:creator>Thomas Modine</dc:creator>
<dc:creator>Stephane Lafitte</dc:creator>
<dc:creator>Azeem Latib</dc:creator>
<dc:creator>Edwin Ho</dc:creator>
<dc:creator>Ythan Goldberg</dc:creator>
<dc:creator>Pinak Shah</dc:creator>
<dc:creator>Charles Nyman</dc:creator>
<dc:creator>Josep Rodés-Cabau</dc:creator>
<dc:creator>Elisabeth Bédard</dc:creator>
<dc:creator>Nicolas Brugger</dc:creator>
<dc:creator>Anna Sannino</dc:creator>
<dc:creator>Michael J Mack</dc:creator>
<dc:creator>Martin B Leon</dc:creator>
<dc:creator>Stephan Windecker</dc:creator>
<dc:creator>TRISCEND study investigators</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transfemoral tricuspid valve replacement and one-year outcomes: the TRISCEND study</dc:title>
<dc:identifier>pmid:37930776</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad667</dc:identifier>
</item>
<item>
<title>A change in the paradigm of antibiotic management in infective endocarditis: are we ready?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930713/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Oct 31:ehad529. doi: 10.1093/eurheartj/ehad529. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930713/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37930713</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad529>10.1093/eurheartj/ehad529</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930713</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nuria Fernández-Hidalgo</dc:creator>
<dc:creator>Ignacio Ferreira-González</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A change in the paradigm of antibiotic management in infective endocarditis: are we ready?</dc:title>
<dc:identifier>pmid:37930713</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad529</dc:identifier>
</item>
<item>
<title>Aortic Dissection in Marfan Syndrome: Protect the Tube of Life</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930286/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 18:S0735-1097(23)07568-X. doi: 10.1016/j.jacc.2023.08.054. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930286/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37930286</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.054>10.1016/j.jacc.2023.08.054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930286</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Alan C Braverman</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Aortic Dissection in Marfan Syndrome: Protect the Tube of Life</dc:title>
<dc:identifier>pmid:37930286</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.054</dc:identifier>
</item>
<item>
<title>Risk of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930285/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In our contemporary cohort, type B dissections are more common than type A dissections and occur at traditional nonsurgical thresholds. The associations of type B dissection with ARR, independent mitral valve surgery, and type II dissection suggest a more severe phenotype in the setting of prolonged life expectancy.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 18:S0735-1097(23)07569-1. doi: 10.1016/j.jacc.2023.08.055. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: With preventive aortic grafting decreasing the incidence of type A dissections in Marfan syndrome (MFS), most dissections are now type B, for which risk factors remain largely uncertain.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: We explored the determinants of type B dissection risk in a large, single-center MFS registry.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Demographic and anthropometric features, cardiovascular disease, and surgical history were compared in patients with MFS with and without type B dissection.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 336 patients with MFS, 47 (14%) experienced a type B dissection (vs type A in 9%). Patients with type B dissection were more likely to have undergone elective aortic root replacement (ARR) (79 vs 46%; P &lt; 0.001). Of the patients, 55% had type B dissection a mean of 13.3 years after ARR, whereas 45% experienced type B dissection before or in the absence of ARR; 41 patients (87%) were aware of their MFS diagnosis before type B dissection. Among those with predissection imaging, the descending aorta was normal or minimally dilated (&lt;4.0 cm) in 88%. In multivariable analyses, patients with type B dissection were more likely to have undergone ARR and independent mitral valve surgery, to have had a type II dissection, and to have lived longer.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In our contemporary cohort, type B dissections are more common than type A dissections and occur at traditional nonsurgical thresholds. The associations of type B dissection with ARR, independent mitral valve surgery, and type II dissection suggest a more severe phenotype in the setting of prolonged life expectancy.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930285/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37930285</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.055>10.1016/j.jacc.2023.08.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930285</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Nupoor Narula</dc:creator>
<dc:creator>Richard B Devereux</dc:creator>
<dc:creator>Eloisa Arbustini</dc:creator>
<dc:creator>Xiaoyue Ma</dc:creator>
<dc:creator>Jonathan W Weinsaft</dc:creator>
<dc:creator>Leonard Girardi</dc:creator>
<dc:creator>Grace P Malonga</dc:creator>
<dc:creator>Mary J Roman</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Risk of Type B Dissection in Marfan Syndrome: The Cornell Aortic Aneurysm Registry</dc:title>
<dc:identifier>pmid:37930285</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.055</dc:identifier>
</item>
<item>
<title>Hot topics in interventional cardiology: left main disease, heavily calcified coronary stenoses, and physiology-guided percutaneous coronary interventions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37930000/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Nov 1;44(41):4295-4299. doi: 10.1093/eurheartj/ehad721.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37930000/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37930000</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad721>10.1093/eurheartj/ehad721</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37930000</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Hot topics in interventional cardiology: left main disease, heavily calcified coronary stenoses, and physiology-guided percutaneous coronary interventions</dc:title>
<dc:identifier>pmid:37930000</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad721</dc:identifier>
</item>
<item>
<title>Associations Between End-Tidal Carbon Dioxide During Pediatric Cardiopulmonary Resuscitation, CPR Quality, and Survival</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929615/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>Background: Supported by laboratory and clinical investigations of adult cardiopulmonary arrest, resuscitation guidelines recommend monitoring end-tidal carbon dioxide (ETCO2) as an indicator of CPR quality but note that "specific values to guide therapy have not been established in children." Methods: This prospective observational cohort study was an NHLBI-funded ancillary study of children in the ICU-RESUScitation trial (NCT02837497). Hospitalized children (≤18 years of age and ≥37 weeks...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.066659. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Supported by laboratory and clinical investigations of adult cardiopulmonary arrest, resuscitation guidelines recommend monitoring end-tidal carbon dioxide (ETCO2) as an indicator of CPR quality but note that "specific values to guide therapy have not been established in children." <b>Methods:</b> This prospective observational cohort study was an NHLBI-funded ancillary study of children in the <i>ICU-RESUS</i>citation trial (NCT02837497). Hospitalized children (≤18 years of age and ≥37 weeks post-gestational age) who received chest compressions of any duration for cardiopulmonary arrest, had an endotracheal or tracheostomy tube at the start of CPR, and had evaluable intra-arrest ETCO2 data were included. The primary exposure was event-level average ETCO2 during the first 10 minutes of CPR (dichotomized as ≥20 mmHg vs. &lt;20 mmHg based on adult literature). The primary outcome was survival to hospital discharge. Secondary outcomes were sustained return of spontaneous circulation (ROSC), survival to discharge with favorable neurologic outcome, and new morbidity among survivors. Poisson regression measured associations between ETCO2 and outcomes as well as the association between ETCO2 and other CPR characteristics: 1) invasively measured systolic and diastolic blood pressures and 2) CPR quality and chest compression mechanics metrics (i.e., time to CPR start; chest compression rate, depth, and fraction; ventilation rate). <b>Results:</b> Among 234 included patients, 133 (57%) had an event-level average ETCO2 ≥20 mmHg. After controlling for <i>a priori</i> covariates, average ETCO2 ≥20 mmHg was associated with higher incidence of survival to hospital discharge (86/133 (65%) versus 48/101 (48%); aRR 1.33, CI95 1.04 - 1.69, p=0.023) and ROSC (95/133 (71%) versus 59/101 (58%); aRR 1.22, CI95 1.00 - 1.49, p=0.046) compared with lower values. ETCO2 ≥20 mmHg was not associated with survival with favorable neurologic outcome or new morbidity among survivors. Average ETCO2 ≥20 mmHg was associated with higher systolic and diastolic blood pressures during CPR, lower CPR ventilation rates, and briefer pre-CPR arrest durations compared with lower values. Chest compression rate, depth, and fraction did not differ between ETCO2 groups. <b>Conclusions:</b> In this multicenter study of children with in-hospital cardiopulmonary arrest, ETCO2 ≥20 mmHg was associated with better outcomes and higher intra-arrest blood pressures, but not with chest compression quality metrics.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929615/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37929615</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066659>10.1161/CIRCULATIONAHA.123.066659</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929615</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Ryan W Morgan</dc:creator>
<dc:creator>Ron W Reeder</dc:creator>
<dc:creator>Dieter Bender</dc:creator>
<dc:creator>Kellimarie K Cooper</dc:creator>
<dc:creator>Stuart H Friess</dc:creator>
<dc:creator>Kathryn Graham</dc:creator>
<dc:creator>Kathleen L Meert</dc:creator>
<dc:creator>Peter M Mourani</dc:creator>
<dc:creator>Robert Murray</dc:creator>
<dc:creator>Vinay M Nadkarni</dc:creator>
<dc:creator>C Nataraj</dc:creator>
<dc:creator>Chella A Palmer</dc:creator>
<dc:creator>Neeraj Srivastava</dc:creator>
<dc:creator>Bradley Tilford</dc:creator>
<dc:creator>Heather A Wolfe</dc:creator>
<dc:creator>Andrew R Yates</dc:creator>
<dc:creator>Robert A Berg</dc:creator>
<dc:creator>Robert M Sutton</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Associations Between End-Tidal Carbon Dioxide During Pediatric Cardiopulmonary Resuscitation, CPR Quality, and Survival</dc:title>
<dc:identifier>pmid:37929615</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066659</dc:identifier>
</item>
<item>
<title>Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929602/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>Background: Among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by high-sensitivity C-reactive protein (hsCRP) is at least as strong a predictor of future cardiovascular events as is residual risk assessed by low-density lipoprotein cholesterol (LDLC). Whether these relationships are present among statin-intolerant patients with higher LDLC levels is uncertain but has implications for the choice of preventive therapies,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.066213. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by high-sensitivity C-reactive protein (hsCRP) is at least as strong a predictor of future cardiovascular events as is residual risk assessed by low-density lipoprotein cholesterol (LDLC). Whether these relationships are present among statin-intolerant patients with higher LDLC levels is uncertain but has implications for the choice of preventive therapies, including bempedoic acid, an agent that reduces both LDLC and hsCRP. <b>Methods:</b> The multinational CLEAR-Outcomes trial (Cholesterol Lowering via Bempedoic Acid, an ACL-Inhibiting Regimen Outcomes Trial) randomly allocated 13970 statin-intolerant patients to 180 mg of oral bempedoic acid daily or matching placebo and followed them for a 4-component composite of incident myocardial infarction, stroke, coronary revascularization, or cardiovascular death, and for all-cause mortality. Quartiles of increasing baseline hsCRP and LDLC were assessed as predictors of future adverse events after adjustment for traditional risk factors and randomized treatment assignment. <b>Results:</b> Compared with placebo, bempedoic acid reduced median hsCRP by 21.6% and mean LDLC levels by 21.1% at 6 months. Baseline hsCRP was significantly associated with the primary composite end point of major cardiovascular events (highest versus lowest hsCRP quartile; hazard ratio [HR], 1.43 [95% CI, 1.24-1.65]), cardiovascular mortality (HR, 2.00 [95% CI, 1.53-2.61]), and all-cause mortality (HR, 2.21 [95% CI, 1.79-2.73]). By contrast, the relationship of baseline LDLC quartile (highest versus lowest) to future events was smaller in magnitude for the primary composite cardiovascular end point (HR, 1.19 [95% CI, 1.04-1.37]) and neutral for cardiovascular mortality (HR, 0.90 [95% CI, 0.70-1.17]) and all-cause mortality (HR, 0.95 [95% CI, 0.78-1.16]). Risks were high for those with elevated hsCRP irrespective of LDLC level. Bempedoic acid demonstrated similar efficacy in reducing cardiovascular events across all levels of hsCRP and LDLC. <b>Conclusions:</b> Among contemporary statin-intolerant patients, inflammation assessed by hsCRP predicted risk for future cardiovascular events and death more strongly than hyperlipidemia assessed by LDLC. Compared with placebo, bempedoic acid had similar efficacy for reducing cardiovascular risk across hsCRP and LDLC strata.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929602/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37929602</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.066213>10.1161/CIRCULATIONAHA.123.066213</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929602</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Paul M Ridker</dc:creator>
<dc:creator>Lei Lei</dc:creator>
<dc:creator>Michael J Louie</dc:creator>
<dc:creator>Tariq Haddad</dc:creator>
<dc:creator>Stephen J Nicholls</dc:creator>
<dc:creator>A Michael Lincoff</dc:creator>
<dc:creator>Peter Libby</dc:creator>
<dc:creator>Steven E Nissen</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance</dc:title>
<dc:identifier>pmid:37929602</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.066213</dc:identifier>
</item>
<item>
<title>A Diagnostic CopyCat: Culture-Negative Infective Endocarditis of a Bioprosthetic Valve Presenting as ANCA Vasculitis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929592/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.067136. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929592/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37929592</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067136>10.1161/CIRCULATIONAHA.123.067136</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929592</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>David E Hamilton</dc:creator>
<dc:creator>Sandro K Cinti</dc:creator>
<dc:creator>Cathryn J Lapedis</dc:creator>
<dc:creator>Kim A Eagle</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Diagnostic CopyCat: Culture-Negative Infective Endocarditis of a Bioprosthetic Valve Presenting as ANCA Vasculitis</dc:title>
<dc:identifier>pmid:37929592</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067136</dc:identifier>
</item>
<item>
<title>Meta-analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929589/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>Background: Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy (LVH) and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease, as penetrance (proportion of G+ who develop disease) is variable, age-dependent, and not reliably predicted. Methods: A systematic search of the literature was performed. We employed random...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.065987. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy (LVH) and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease, as penetrance (proportion of G+ who develop disease) is variable, age-dependent, and not reliably predicted. <b>Methods:</b> A systematic search of the literature was performed. We employed random effects generalized linear mixed model meta-analyses to contrast the cross-sectional prevalence and penetrance of sarcomere genes in two different contexts: clinically-based studies on patients and families with HCM versus population/community-based studies. Longitudinal family/clinical studies were additionally analyzed to investigate the rate of phenotypic conversion from subclinical to overt HCM during follow-up. <b>Results:</b> 455 full text manuscripts were assessed. In family/clinical studies, the prevalence of sarcomere variants in patients diagnosed with HCM was 34%. The penetrance across all genes in non-proband relatives carrying P/LP variants identified during cascade screening was 57% (95% confidence interval [CI] [52,63]) and the mean age of HCM diagnosis was 38 years (95% CI [36, 40]). Penetrance varied from ~32% for myosin light chain (<i>MYL3</i>) to ~55% for myosin binding protein C (<i>MYBPC3</i>), ~60% troponin T (<i>TNNT2</i>) and troponin I (<i>TNNI3</i>), and ~65% for myosin heavy chain (<i>MYH7</i>). Population-based genetic studies demonstrate that P/LP sarcomere variants are present in the background population, but at a low prevalence of &lt;1%. The penetrance of HCM in incidentally identified P/LP variant carriers was also substantially lower; approximatively 11%, ranging from 0% in Atherosclerosis Risk in Communities to 18% in UK Biobank. In longitudinal family studies, the pooled phenotypic conversion across all genes was 15% over an average of ~8 years of follow up, starting from a mean age of ~16 years. However, short-term gene-specific phenotypic conversion varied between ~12% for <i>MYBPC3</i> to ~23% for <i>MYH7</i>. <b>Conclusions:</b> The penetrance of P/LP variants is highly variable and influenced by currently undefined and context-dependent genetic and environmental factors. Additional longitudinal studies are needed to improve understanding of true lifetime penetrance in families and in the community, and to identify drivers of the transition from subclinical to overt HCM.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929589/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37929589</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.065987>10.1161/CIRCULATIONAHA.123.065987</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929589</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Constantin-Cristian Topriceanu</dc:creator>
<dc:creator>Alexandre C Pereira</dc:creator>
<dc:creator>James C Moon</dc:creator>
<dc:creator>Gabriella Captur</dc:creator>
<dc:creator>Carolyn Y Ho</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Meta-analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy</dc:title>
<dc:identifier>pmid:37929589</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.065987</dc:identifier>
</item>
<item>
<title>Myeloid Cell Derived IL1β Contributes to Pulmonary Hypertension in HFpEF</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929582/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: We report a novel model for the study of PH and right heart remodeling in HFpEF, and we identify myeloid cell-derived IL-1β as an important contributor to PH in HFpEF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Nov 6. doi: 10.1161/CIRCRESAHA.123.323119. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Pulmonary hypertension (PH) in heart failure with preserved ejection fraction (HFpEF) is a common and highly morbid syndrome, but mechanisms driving PH-HFpEF are poorly understood. We sought to determine whether a well-accepted murine model of HFpEF also displays features of PH, and we sought to identify pathways that might drive early remodeling of the pulmonary vasculature in HFpEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Eight-week-old male and female C57BL/6J mice received either N<sup>γ</sup>-nitro-L-arginine methyl ester and high-fat diet or control water and diet for 2, 5, and 12 weeks. The db/db mice were studied as a second model of HFpEF. Early pathways regulating PH were identified by bulk and single-cell RNA sequencing. Findings were confirmed by immunostain in lungs of mice or lung slides from clinically performed autopsies of patients with PH-HFpEF. ELISA was used to verify IL-1β (interleukin-1 beta) in mouse lung, mouse plasma, and also human plasma from patients with PH-HFpEF obtained at the time of right heart catheterization. Clodronate liposomes and an anti-IL-1β antibody were utilized to deplete macrophages and IL-1β, respectively, to assess their impact on pulmonary vascular remodeling in HFpEF in mouse models.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: N<sup>γ</sup>-nitro-L-arginine methyl ester/high-fat diet-treated mice developed PH, small vessel muscularization, and right heart dysfunction. Inflammation-related gene ontologies were overrepresented in bulk RNA sequencing analysis of whole lungs, with an increase in CD68<sup>+</sup> cells in both murine and human PH-HFpEF lungs. Cytokine profiling showed an increase in IL-1β in mouse and human plasma. Finally, clodronate liposome treatment in mice prevented PH in N<sup>γ</sup>-nitro-L-arginine methyl ester/high-fat diet-treated mice, and IL-1β depletion also attenuated PH in N<sup>γ</sup>-nitro-L-arginine methyl ester/high-fat diet-treated mice.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: We report a novel model for the study of PH and right heart remodeling in HFpEF, and we identify myeloid cell-derived IL-1β as an important contributor to PH in HFpEF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929582/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37929582</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323119>10.1161/CIRCRESAHA.123.323119</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929582</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Vineet Agrawal</dc:creator>
<dc:creator>Jonathan A Kropski</dc:creator>
<dc:creator>Jason J Gokey</dc:creator>
<dc:creator>Elizabeth Kobeck</dc:creator>
<dc:creator>Matthew B Murphy</dc:creator>
<dc:creator>Katherine T Murray</dc:creator>
<dc:creator>Niki L Fortune</dc:creator>
<dc:creator>Christy S Moore</dc:creator>
<dc:creator>David F Meoli</dc:creator>
<dc:creator>Ken Monahan</dc:creator>
<dc:creator>Yan Ru Su</dc:creator>
<dc:creator>Thomas Blackwell</dc:creator>
<dc:creator>Deepak K Gupta</dc:creator>
<dc:creator>Megha H Talati</dc:creator>
<dc:creator>Santhi Gladson</dc:creator>
<dc:creator>Erica J Carrier</dc:creator>
<dc:creator>James D West</dc:creator>
<dc:creator>Anna R Hemnes</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Myeloid Cell Derived IL1β Contributes to Pulmonary Hypertension in HFpEF</dc:title>
<dc:identifier>pmid:37929582</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323119</dc:identifier>
</item>
<item>
<title>A Tale of Two Maladies: An Interplay of Mendelian Principles</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929575/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.067135. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929575/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37929575</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067135>10.1161/CIRCULATIONAHA.123.067135</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929575</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Reynaldo H Sanchez</dc:creator>
<dc:creator>Veena Rajaram</dc:creator>
<dc:creator>Nicholas S Hendren</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>A Tale of Two Maladies: An Interplay of Mendelian Principles</dc:title>
<dc:identifier>pmid:37929575</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067135</dc:identifier>
</item>
<item>
<title>Non-ischemic or Dual Cardiomyopathy in Patients with Coronary Artery Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37929565/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>Background: Randomized trials in obstructive coronary artery disease (CAD) have largely shown no prognostic benefit from coronary revascularization. While there are several potential reasons for the lack of benefit, an underexplored possible reason is the presence of coincidental non-ischemic cardiomyopathy (NICM). We investigated the prevalence and prognostic significance of NICM in patients with CAD (CAD-NICM). Methods: We conducted a registry study of consecutive patients with obstructive CAD...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Nov 6. doi: 10.1161/CIRCULATIONAHA.123.067032. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one"><b>Background:</b> Randomized trials in obstructive coronary artery disease (CAD) have largely shown no prognostic benefit from coronary revascularization. While there are several potential reasons for the lack of benefit, an underexplored possible reason is the presence of coincidental non-ischemic cardiomyopathy (NICM). We investigated the prevalence and prognostic significance of NICM in patients with CAD (CAD-NICM). <b>Methods:</b> We conducted a registry study of consecutive patients with obstructive CAD on coronary angiography who underwent contrast-enhanced cardiovascular magnetic resonance imaging (CMR) for the assessment of ventricular function and scar at 4 hospitals from 2004 to 2020. We identified the presence and cause of cardiomyopathy using CMR and coronary angiography data, blinded to clinical outcomes. The primary outcome was a composite of all-cause death or heart failure (HF) hospitalization, and secondary outcomes were all-cause death, HF hospitalization, and cardiovascular death. <b>Results:</b> Among 3,023 patients (median age 66 years, 76% men), 18.2% had no cardiomyopathy (CAD+noCM), 64.8% had ischemic cardiomyopathy (CAD+ICM), 9.3% had CAD+NICM, and 7.7% had dual cardiomyopathy (CAD+dualCM) defined as both ICM and NICM. Thus, 16.9% had CAD+NICM or dualCM. During a median follow-up of 4.8 years (interquartile range, 2.9, 7.6), 1,116 patients experienced the primary outcome. In Cox multivariable analysis, CAD+NICM or dualCM was independently associated with a higher risk of the primary outcome compared with CAD+ICM [adjusted hazard ratio (HR) 1.23; 95% confidence interval (CI) 1.06-1.43; P = 0.007] after adjustment for potential confounders. The risks of the secondary outcomes of all-cause death and HF hospitalization were also higher with CAD+NICM or dualCM (HR 1.21; 95% CI 1.02-1.43; P = 0.032 and HR 1.37; 95% CI 1.11-1.69; P = 0.003 respectively), while the risk of cardiovascular death did not differ from that of CAD+ICM (HR 1.15; 95% CI 0.89-1.48; P = 0.28). <b>Conclusions:</b> In patients with CAD referred for clinical CMR, NICM or dualCM was identified in 1 of every 6 patients and was associated with worse long-term outcomes compared with ICM. In patients with obstructive CAD, coincidental NICM or dualCM may contribute to the lack of prognostic benefit from coronary revascularization.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37929565/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37929565</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.123.067032>10.1161/CIRCULATIONAHA.123.067032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37929565</guid>
<pubDate>Mon, 06 Nov 2023 06:00:00 -0500</pubDate>
<dc:creator>Parag Bawaskar</dc:creator>
<dc:creator>Nicholas Thomas</dc:creator>
<dc:creator>Khaled F Ismail</dc:creator>
<dc:creator>Yugene Guo</dc:creator>
<dc:creator>Sanya Chhikara</dc:creator>
<dc:creator>Pal Satyajit Singh Athwal</dc:creator>
<dc:creator>Alison Ranum</dc:creator>
<dc:creator>Achal Jadhav</dc:creator>
<dc:creator>Abel Hooker Mendez</dc:creator>
<dc:creator>Ishan Nadkarni</dc:creator>
<dc:creator>Dominic Roger Frerichs</dc:creator>
<dc:creator>Pratik Srinivas Velangi</dc:creator>
<dc:creator>Tesfatsiyon Ergando</dc:creator>
<dc:creator>Hassan Akram</dc:creator>
<dc:creator>Adinan Kanda</dc:creator>
<dc:creator>Chetan Shenoy</dc:creator>
<dc:date>2023-11-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Non-ischemic or Dual Cardiomyopathy in Patients with Coronary Artery Disease</dc:title>
<dc:identifier>pmid:37929565</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.123.067032</dc:identifier>
</item>
<item>
<title>Long-term outcomes and device failure after TAVI</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37923830/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 3. doi: 10.1038/s41569-023-00954-3. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37923830/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37923830</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00954-3>10.1038/s41569-023-00954-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37923830</guid>
<pubDate>Sat, 04 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Marco Barbanti</dc:creator>
<dc:creator>John G Webb</dc:creator>
<dc:date>2023-11-04</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Long-term outcomes and device failure after TAVI</dc:title>
<dc:identifier>pmid:37923830</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00954-3</dc:identifier>
</item>
<item>
<title>The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37923829/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>An intense, stereotyped inflammatory response occurs in response to ischaemic and non-ischaemic injury to the myocardium. The NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome is a finely regulated macromolecular protein complex that senses the injury and triggers and amplifies the inflammatory response by activation of caspase 1; cleavage of pro-inflammatory cytokines, such as pro-IL-1β and pro-IL-18, to their mature forms; and induction of inflammatory cell death...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2023 Nov 3. doi: 10.1038/s41569-023-00946-3. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">An intense, stereotyped inflammatory response occurs in response to ischaemic and non-ischaemic injury to the myocardium. The NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome is a finely regulated macromolecular protein complex that senses the injury and triggers and amplifies the inflammatory response by activation of caspase 1; cleavage of pro-inflammatory cytokines, such as pro-IL-1β and pro-IL-18, to their mature forms; and induction of inflammatory cell death (pyroptosis). Inhibitors of the NLRP3 inflammasome and blockers of IL-1β and IL-18 activity have been shown to reduce injury to the myocardium and pericardium, favour resolution of the inflammation and preserve cardiac function. In this Review, we discuss the components of the NLRP3 inflammasome and how it is formed and activated in various ischaemic and non-ischaemic cardiac pathologies (acute myocardial infarction, cardiac dysfunction and remodelling, atherothrombosis, myocarditis and pericarditis, cardiotoxicity and cardiac sarcoidosis). We also summarize current preclinical and clinical evidence from studies of agents that target the NLRP3 inflammasome and related cytokines.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37923829/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37923829</a> | DOI:<a href=https://doi.org/10.1038/s41569-023-00946-3>10.1038/s41569-023-00946-3</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37923829</guid>
<pubDate>Sat, 04 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Stefano Toldo</dc:creator>
<dc:creator>Antonio Abbate</dc:creator>
<dc:date>2023-11-04</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases</dc:title>
<dc:identifier>pmid:37923829</dc:identifier>
<dc:identifier>doi:10.1038/s41569-023-00946-3</dc:identifier>
</item>
<item>
<title>Circuit-specific gene therapy reverses core symptoms in a primate Parkinson's disease model</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37922901/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20231107031103&amp;v=2.17.9.post6+86293ac
      <description>Parkinson's disease (PD) is a debilitating neurodegenerative disorder. Its symptoms are typically treated with levodopa or dopamine receptor agonists, but its action lacks specificity due to the wide distribution of dopamine receptors in the central nervous system and periphery. Here, we report the development of a gene therapy strategy to selectively manipulate PD-affected circuitry. Targeting striatal D1 medium spiny neurons (MSNs), whose activity is chronically suppressed in PD, we engineered...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Oct 30:S0092-8674(23)01086-3. doi: 10.1016/j.cell.2023.10.004. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Parkinson's disease (PD) is a debilitating neurodegenerative disorder. Its symptoms are typically treated with levodopa or dopamine receptor agonists, but its action lacks specificity due to the wide distribution of dopamine receptors in the central nervous system and periphery. Here, we report the development of a gene therapy strategy to selectively manipulate PD-affected circuitry. Targeting striatal D1 medium spiny neurons (MSNs), whose activity is chronically suppressed in PD, we engineered a therapeutic strategy comprised of a highly efficient retrograde adeno-associated virus (AAV), promoter elements with strong D1-MSN activity, and a chemogenetic effector to enable precise D1-MSN activation after systemic ligand administration. Application of this therapeutic approach rescues locomotion, tremor, and motor skill defects in both mouse and primate models of PD, supporting the feasibility of targeted circuit modulation tools for the treatment of PD in humans.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37922901/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20231107031103&v=2.17.9.post6+86293ac">37922901</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.10.004>10.1016/j.cell.2023.10.004</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37922901</guid>
<pubDate>Fri, 03 Nov 2023 06:00:00 -0400</pubDate>
<dc:creator>Yefei Chen</dc:creator>
<dc:creator>Zexuan Hong</dc:creator>
<dc:creator>Jingyi Wang</dc:creator>
<dc:creator>Kunlin Liu</dc:creator>
<dc:creator>Jing Liu</dc:creator>
<dc:creator>Jianbang Lin</dc:creator>
<dc:creator>Shijing Feng</dc:creator>
<dc:creator>Tianhui Zhang</dc:creator>
<dc:creator>Liang Shan</dc:creator>
<dc:creator>Taian Liu</dc:creator>
<dc:creator>Pinyue Guo</dc:creator>
<dc:creator>Yunping Lin</dc:creator>
<dc:creator>Tian Li</dc:creator>
<dc:creator>Qian Chen</dc:creator>
<dc:creator>Xiaodan Jiang</dc:creator>
<dc:creator>Anan Li</dc:creator>
<dc:creator>Xiang Li</dc:creator>
<dc:creator>Yuantao Li</dc:creator>
<dc:creator>Jonathan J Wilde</dc:creator>
<dc:creator>Jin Bao</dc:creator>
<dc:creator>Ji Dai</dc:creator>
<dc:creator>Zhonghua Lu</dc:creator>
<dc:date>2023-11-03</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Circuit-specific gene therapy reverses core symptoms in a primate Parkinson's disease model</dc:title>
<dc:identifier>pmid:37922901</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.10.004</dc:identifier>
</item>





























</channel>
</rss>